Suzetrigine (SUZ)

DRUG3 trials

Sponsors

Vertex Pharmaceuticals Incorporated, University of California, Irvine, Jacob Lensing

Conditions

Acute PainPain ControlRib Fractures

Phase 3

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

CompletedNCT05558410

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2022-10-10End: 2023-09-11Updated: 2025-07-01

Phase 4

Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures

Enrolling by invitationNCT07145346

University of California, IrvineRib Fractures

Start: 2025-11-13End: 2027-08-31Target: 80Updated: 2025-12-08

RCT: Suzetrigine vs Norco for Post-op Pain

Not yet recruitingNCT07195669

Jacob LensingPain Control

Start: 2025-10-01End: 2026-01-30Target: 76Updated: 2025-09-29

Related Papers

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials

Anesthesiology2025-03-2128 citations